Market Recap Check: Allogene Therapeutics Inc (ALLO)’s Negative Finish at 2.32, Up/Down -3.73

Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

The price of Allogene Therapeutics Inc (NASDAQ: ALLO) closed at $2.32 in the last session, down -3.73% from day before closing price of $2.41. In other words, the price has decreased by -$3.73 from its previous closing price. On the day, 1.64 million shares were traded. ALLO stock price reached its highest trading level at $2.41 during the session, while it also had its lowest trading level at $2.3.


We take a closer look at ALLO’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 12.80 and its Current Ratio is at 12.80. In the meantime, Its Debt-to-Equity ratio is 0.21 whereas as Long-Term Debt/Eq ratio is at 0.19.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Piper Sandler on May 31, 2024, initiated with a Overweight rating and assigned the stock a target price of $11.

Insider Transactions:

An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on May 30 ’24 when Humer Franz B sold 11,200 shares for $2.34 per share. The transaction valued at 26,181 led to the insider holds 255,253 shares of the business.

Belldegrun Arie bought 1,724,137 shares of ALLO for $4,999,997 on May 16 ’24. The Director now owns 1,724,137 shares after completing the transaction at $2.90 per share. On Jan 30 ’24, another insider, Parker Geoffrey M., who serves as the CHIEF FINANCIAL OFFICER of the company, bought 190 shares for $3.60 each. As a result, the insider paid 683 and bolstered with 819,590 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ALLO now has a Market Capitalization of 484378880 and an Enterprise Value of 107365840. For the stock, the TTM Price-to-Sale (P/S) ratio is 3725.92 while its Price-to-Book (P/B) ratio in mrq is 0.86. Its current Enterprise Value per Revenue stands at 1234.09 whereas that against EBITDA is -0.397.

Stock Price History:

Over the past 52 weeks, ALLO has reached a high of $6.05, while it has fallen to a 52-week low of $2.23. The 50-Day Moving Average of the stock is -26.75%, while the 200-Day Moving Average is calculated to be -32.71%.

Shares Statistics:

According to the various share statistics, ALLO traded on average about 2.49M shares per day over the past 3-months and 3043080 shares per day over the past 10 days. A total of 208.78M shares are outstanding, with a floating share count of 121.11M. Insiders hold about 41.99% of the company’s shares, while institutions hold 50.59% stake in the company. Shares short for ALLO as of 1715731200 were 36428594 with a Short Ratio of 14.61, compared to 1713139200 on 31360608. Therefore, it implies a Short% of Shares Outstanding of 36428594 and a Short% of Float of 33.029997.

Earnings Estimates

As of right now, 16.0 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.35 for the current quarter, with a high estimate of -$0.28 and a low estimate of -$0.39, while EPS last year was -$0.53. The consensus estimate for the next quarter is -$0.36, with high estimates of -$0.26 and low estimates of -$0.45.

Analysts are recommending an EPS of between -$1.19 and -$1.91 for the fiscal current year, implying an average EPS of -$1.49. EPS for the following year is -$1.55, with 16.0 analysts recommending between -$1.21 and -$2.02.

Most Popular